Nonalcoholic steatohepatitis will pose clinical, economic burden
Nonalcoholic steatohepatitis (NASH) is expected to pose a significant clinical and economic burden during the next 20 years for U.S.
Read more
Nonalcoholic steatohepatitis (NASH) is expected to pose a significant clinical and economic burden during the next 20 years for U.S.
Read moreTaxing sugar-sweetened beverages by the amount of sugar they contain, rather than by the liquid volume of these drinks, as
Read more